The Effects of C. lacerata on Insulin Resistance in Type 2 Diabetes Patients

Table 1

Subject characteristics at baseline.

	Total ()	Placebo group ()		C. lacerata group ()	value
Gender (M/F)	57/27	28/15		29/12	NS^b
Age (yrs)					NS^a
BMI (kg/m^2)					NS
DM durations (yrs)					NS
DM medication
Monotherapy	26 (30.9%)	9 (20.9%)		17 (41.5%)	NS^b
Dual therapy	21 (25%)	12 (27.9%)		9 (22.0%)
≥Triple therapy	37 (44%)	22 (51.2%)		15 (36.6%)
Statin medication
User	56 (66.7%)	29 (67.4%)		27 (65.9%)	NS^b
Nonuser	28 (33.3%)	14 (32.6%)		14 (34.1%)
SBP (mmHg)					NS^a
DBP (mmHg)					NS
FPG (mg/dL)					NS
Hba1c (%)					NS

Data are presented as (SD) or as numbers (%). ^aAnalyzed by independent -tests and the value represents the comparison to the placebo group. ^bAnalyzed by chi-square. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose.